First approval of TAAV synthetic DNA material for use in clinical trial

TAAV Biomanufacturing Solutions, SL (TAAV) announced today the anticipated first use in a clinical trial of company-manufactured doggybone DNA (dbDNA)1, a precisely engineered synthetic DNA material. TAAV-produced dbDNA is a component of an Asklepios BioPharmaceutical, Inc. (AskBio) gene therapy candidate for the treatment of early-stage Huntington's disease, which was recently authorized by France's National Agency for Safety of Medicines and Health Products (ANSM) for an upcoming Phase I/II clinical trial.